ACUR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 19:40):

Stats
Šios dienos apimtis	780.00
Vidutinė apimtis	1 050.00
Rinkos kapitalizacija	660 018
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Ross George K	Buy	50 000	Common Stock
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Skelly William G	Buy	50 000	Common Stock
2024-01-02	Skelly William G	Sell	50 000	Restricted Stock Units (2021 Plan)

INSIDER POWER
7.84
Last 100 transactions
Buy: 88 557 065 \| Sell: 8 647 538

ACURA PHARMACEUTICALS INC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ACURA PHARMACEUTICALS INC Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2020
Pajamos:	$3.57M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.0400

FY	2019
Pajamos:	$2.66M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.140

Financial Reports:

No articles found.

ACURA PHARMACEUTICALS INC

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.